A detailed history of Hussman Strategic Advisors, Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Hussman Strategic Advisors, Inc. holds 315,000 shares of BCRX stock, worth $3.5 Million. This represents 0.61% of its overall portfolio holdings.

Number of Shares
315,000
Holding current value
$3.5 Million
% of portfolio
0.61%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 05, 2025

BUY
$7.06 - $9.39 $2.22 Million - $2.96 Million
315,000 New
315,000 $2.36 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $2.07B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Hussman Strategic Advisors, Inc. Portfolio

Follow Hussman Strategic Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hussman Strategic Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hussman Strategic Advisors, Inc. with notifications on news.